2026-527365-30-00Not yet recruitingPhase 1/2
A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 30 Jun 2026
- Start date
- 1 Sept 2026
- Lead sponsor
- Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
- Diseases
- Metastatic breast cancer
- EU CT number
- 2026-527365-30-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 18
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced breast cancer that is HER2-positive. It tests ARI-HER2 (HER2BBz CAR-T cells) as a first-in-human treatment.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
- Disease stage
- Advanced breast cancer that is HER2-positive.
- Biomarker or test result
- HER2-positive
Main reasons for not taking part
- Healthy volunteers cannot join.
Read by machine on 9 Nov 2026.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clinic de Barcelona | Barcelona | Spain | Not yet recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Not yet recruiting |
| Clínica Universidad de navarra | Pamplona | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.